TY - JOUR
T1 - Treatment with a gonadotropin-releasing-hormone analog and attainment of full height potential in a male monozygotic twin with gonadotropin-releasing hormone-dependent precocious puberty
AU - Ishii, T.
AU - Sato, S.
AU - Anzo, M.
AU - Sasaki, G.
AU - Hasegawa, T.
AU - Tamai, S.
AU - Matsuo, N.
N1 - Funding Information:
Acknowledgements We would like to thank Mitsubishi Kagaku Bio-clinical Laboratories Inc. for assaying HLA loci and VNTR markers. The present study was supported by the Pharmacia & Upjohn Fund for Growth & Development Research.
PY - 1999
Y1 - 1999
N2 - We report on a pair of male monozygotic twins, one unaffected and the other affected with gonadotropin-releasing hormone (GnRH)-dependent precocious puberty, and discuss the role of treatment with a GnRH analog in the attainment of full height potential in GnRH-dependent precocious puberty. At 1.6 years of age, the affected twin was studied for tall stature (+3.8 SD), and was diagnosed as having GnRH-dependent precocious puberty due to a hypothalamic hamartoma of the tuber cinereum. He was treated with oral cyproterone acetate (110-170 mg/m2 daily) from 1.8 through 5.0 years of age, with oral cyproterone acetate and intranasal buserelin acetate (700-900 μg/m2 daily) from 5.0 through 7.5 years, and with intranasal buserelin acetate alone (1100-1400 μg/m2 daily) from 7.5 through 12.6 years. He attained a final height of 171.0 cm at 14.9 years of age (+0.10 SD) and his twin 170.0 cm at 15.3 years of age (-0.10 SD), with their target height being 174.5 ± 9.0 cm. Conclusion: This study indicates that GnRH analog treatment may preserve near full height potential in some patients with GnRH-dependent precocious puberty.
AB - We report on a pair of male monozygotic twins, one unaffected and the other affected with gonadotropin-releasing hormone (GnRH)-dependent precocious puberty, and discuss the role of treatment with a GnRH analog in the attainment of full height potential in GnRH-dependent precocious puberty. At 1.6 years of age, the affected twin was studied for tall stature (+3.8 SD), and was diagnosed as having GnRH-dependent precocious puberty due to a hypothalamic hamartoma of the tuber cinereum. He was treated with oral cyproterone acetate (110-170 mg/m2 daily) from 1.8 through 5.0 years of age, with oral cyproterone acetate and intranasal buserelin acetate (700-900 μg/m2 daily) from 5.0 through 7.5 years, and with intranasal buserelin acetate alone (1100-1400 μg/m2 daily) from 7.5 through 12.6 years. He attained a final height of 171.0 cm at 14.9 years of age (+0.10 SD) and his twin 170.0 cm at 15.3 years of age (-0.10 SD), with their target height being 174.5 ± 9.0 cm. Conclusion: This study indicates that GnRH analog treatment may preserve near full height potential in some patients with GnRH-dependent precocious puberty.
KW - Final height
KW - GnRH analog
KW - Hypothalamic hamartoma
KW - Monozygotic twins
KW - Precocious puberty
UR - http://www.scopus.com/inward/record.url?scp=0032820078&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032820078&partnerID=8YFLogxK
U2 - 10.1007/s004310051245
DO - 10.1007/s004310051245
M3 - Article
C2 - 10541952
AN - SCOPUS:0032820078
SN - 0340-6199
VL - 158
SP - 933
EP - 935
JO - European Journal of Pediatrics
JF - European Journal of Pediatrics
IS - 11
ER -